Arcutis Biotherapeutics to Discuss Positive Topline Data from Phase 2b Study of ARQ-154 - Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the Arcutis conference call. As a reminder, this conference call is being recorded. I would like to introduce your host for today's conference, Ms. Heather Armstrong, Vice President of Investor Relations and Corporate Communications. You may begin.
Thank you. Good morning and welcome to our conference call and webcast to discuss our positive top line data from our Phase 2B study of roflumilast foam in patients with scalp and body psoriasis.
The slides used in today's webcast can be found in the Events and Presentation in the Investor Section of our website at arcutis.com.
I'm joined on the call today by Frank Watanabe, President and CEO; Dr. Patrick Burnett, Chief Medical Officer; Ken Lock, Chief Commercial Officer; and John Smither, CFO.
Before we begin, I must remind you that safe harbor rules covering our remarks today and any forward-looking statements that we may make. These
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |